Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT02312063 Completed - Clinical trials for Diabetes Mellitus, Type 2

Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes

DIET
Start date: February 2015
Phase: Phase 4
Study type: Interventional

In a prospective, randomized case-controlled study, the investigators hope to demonstrate a positive correlation of plasma levels of EPA and DHA as well as fish intake with the HbA1c-lowering effect of sitagliptin but not with the active comparator glimepiride.

NCT ID: NCT02311075 Completed - Clinical trials for Diabetes Mellitus, Type 2

Mechanisms of Endothelial Dysfunction in Type 2 Diabetes

DIAB-EETs
Start date: December 2014
Phase: N/A
Study type: Interventional

Endothelial dysfunction of conduit arteries plays an important role in the development of cardiovascular complications associated with type 2 diabetes. In order to propose targeted therapeutic approaches, this study aim to determine the mechanisms involved in endothelial dysfunction of conduit arteries in these patients.

NCT ID: NCT02308683 Completed - Diabetes Clinical Trials

Effects of Moringa Oleifera on hsCRP and Hgba1c Level of Patients in Ospital ng Maynila Medical Center Diabetic Clinic

Start date: August 2014
Phase: Phase 1
Study type: Interventional

Current evidence supports a central role of inflammation in the pathogenesis of atherosclerosis and diabetes [57-60]. Diabetes Mellitus type 2 is an inflammatory atherothrombotic condition associated with high prevalence of thrombotic cardiovascular disease. In patient with DM type 2, this inflammation is reflected by elevated plasma levels of several biomarkers of inflammation such as C-reactive protein (CRP) [51-55]. HsCRP is considered as a strong predictive of cardiovascular risks and death [53, 61-72]. Besides its predictive role in determining cardiovascular risk, there is some evidence that CRP may represent an active participant in atherogenesis [54]. CRP is expressed in human atherosclerotic plaques and both vascular cells and monocytes/macrophages appear to represent a significant source of CRP in the inflammatory vessel wall [54]. Among the DM risk factors (like hypertension, atherogenic dyslipidemia, insulin resistance, impaired fibrinolysis, inflammatory profile), definitely, inflammation is the neglected one. Moringa oleifera has been suggested to exert anti-inflammatory effects [42][43][45] and hypoglycemic property [80]. As with many reports of the nutritional or medicinal value of a natural product, there are an alarming number of purveyors of "healthful" food who are now promoting M. oleifera as a panacea. While much of this recent enthusiasm indeed appears to be justified, it is critical to separate scientific evidence from anecdote. Herein, the investigators will investigate the effects of Moringa oleifera leaves supplementation on levels of inflammatory marker specifically hsCRP, hgbA1c level and clinical outocome in diabetic patients through a cohort study.

NCT ID: NCT02307968 Completed - Diabetes Mellitus Clinical Trials

Comparative Study of Insulin Therapy Between Inner and Outer Upper Thigh

CUSTIOT
Start date: October 2014
Phase: N/A
Study type: Observational

To observe the patient's preference, pain perception, and usability between inner and outer upper thigh for insulin therapy. To add another injection site for insulin therapy.

NCT ID: NCT02306681 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes

Start date: October 30, 2014
Phase:
Study type: Observational

This study is conducted globally. The aim of this study is to describe the proportion of patients with hypoglycaemic episodes and estimate the incidence of various types of hypoglycaemia in the retrospective and prospective periods.

NCT ID: NCT02306122 Completed - Hypertension Clinical Trials

Pharmacy Home Adherence Reporting and Monitoring Outcomes Study

PHARxMOS
Start date: March 2011
Phase: N/A
Study type: Interventional

This study is a pilot test of an intervention that delivers timely diagnostic information about medication nonadherence to doctors, and then offers the services of clinical pharmacists to treat these nonadherence problems. Participating doctors will be notified when a patient is 10 days late refilling a medication for diabetes, hypertension, or hypercholesterolemia. In one randomization arm the pharmacist will contact the patient as the default option (with no action required by the doctor), and in the other the pharmacist will contact the patient only if the doctor actively chooses that the pharmacist take action. Patients of participating doctors will be randomized to 1) one of these two pharmacist options, 2) an information only control arm in which the doctor gets adherence information but does not have access to a pharmacist for that patient, and 3) a no information control arm. The investigators' central hypothesis is that the pharmacist will be consulted more often when intervention by the pharmacist is the default outcome and that the default pharmacist intervention will be the most beneficial for adherence outcomes.

NCT ID: NCT02305381 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

SUSTAIN™ 5
Start date: December 1, 2014
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes.

NCT ID: NCT02305355 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia

Start date: February 2009
Phase: Phase 4
Study type: Interventional

Assess efficacy and safety of Omacor® 4g with statin treatment for lowering TG levels in subjects with type 2 Diabetes combined with hyperlipidemia

NCT ID: NCT02304627 Completed - Healthy Clinical Trials

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Start date: November 24, 2014
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe. The aim of the trial is to investigate the effect of food on the pharmacokinetics (the exposure of the trial drug in the body) of NNC0123-0000-0338 in a tablet formulation in healthy subjects.

NCT ID: NCT02304497 Completed - Diabetes Mellitus Clinical Trials

PRF Growth Factors Levels in Diabetic Patients With Chronic Periodontitis

Start date: March 2013
Phase: N/A
Study type: Observational [Patient Registry]

Diabetic patients may show different release of growth factors when microvascular complications such as; retinopathy or periodontitis are seen. Diabetes have an adverse effect on periodontal health and periodontal infection have an adverse effect on glycemic control and incidence of diabetes complications. Therefore, the investigators hypothesize that growth factors levels releasing from platelet rich fibrin (PRF) in diabetes mellitus (DM) may be decrease because of periodontitis is considered to be the sixth microvascular complication of diabetes or diabetes may have inductive effect on PRF growth factors levels in periodontal disease. Determination of PRF growth factors levels may be beneficial to treatment of diabetic patient with periodontal disease by using PRF.